FIELD: medicine.
SUBSTANCE: invention relates to a method for diagnosing the risk of developing Alzheimer’s disease or the presence of severe AD in a subject and can be used in medicine. Suggested methods include measuring in a biological sample of a subject a level of at least five biomarkers AD selected from a neurotrophic factor from brain tissue (BDNF), insulin-like growth factor 1 (IGF-1), tumor growth factor beta-1 (TGF-beta 1), vascular endothelioma growth factor (VEGF), interleukin 18 (IL-18) and monocyte chemotactic protein-1 (MCP-1), wherein increasing IL-18 and MCP-1 and reducing BDNF, IGF-1, VEGF and TGF-beta 1 in comparison with the control indicates the presence or risk of developing AD, and increasing IL-18 and VEGF and reducing BDNF, IGF-1, MCP-1 and TGF-beta 1 in comparison with the control indicates the presence of severe AD. Proposed are novel highly specific methods and applications of said biomarkers, which enable differential diagnosis between the presence or risk of developing AD and severe AD.
EFFECT: biomarker and methods for early diagnosis of Alzheimer’s disease are proposed.
13 cl, 4 ex, 5 tbl, 2 dwg
